Podoplanin expression in various types of oral dysplasia and oral squamous cell carcinoma.

Fatemeh Mashhadiabbas, Maryam M Chafjiri, Mahmood Dashti, Muhammad A Mudasser, Sanaz Gholami
Author Information
  1. Fatemeh Mashhadiabbas: Shahid Beheshti University of Medical Sciences, Faculty of Dentistry, Department of Oral & Maxillofacial Pathology, Tehran, Iran.
  2. Maryam M Chafjiri: Shahid Beheshti University of Medical Sciences, Faculty of Dentistry, Department of Oral & Maxillofacial Pathology, Tehran, Iran.
  3. Mahmood Dashti: Dentofacial Deformities Research Center, Research Institute of Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  4. Muhammad A Mudasser: Department of Orthodontics, Dr. Ishrat Ul Ibad Khan Institute of OralHealth Sciences, Dow University of Health Sciences, Karachi, Pakistan.
  5. Sanaz Gholami: Shahid Beheshti University of Medical Sciences, Faculty of Dentistry, Department of Oral & Maxillofacial Pathology, Tehran, Iran.

Abstract

Objective: This study was aimed at investigating the roles of Podoplanin (PDPN) as a marker associated with malignant development, progression, and poor prognosis in oral leukoplakia and various forms of oral squamous cell carcinoma (OSCC), particularly in relation to the extent of invasion.
Methods: Immunohistochemical analysis of PDPN was conducted on 77 histologically confirmed, formalin-fixed, paraffin-embedded samples representing various degrees of OSCC invasion and dysplasia grades.
Results: The samples were analyzed with Fisher's exact test and the Kruskal-Wallis test. Significant associations between sample type and the intensity, percentage, distribution, location, inflammation, and lymphatic vessel involvement according to staining were observed (p < 0.05). The PDPN staining score progressively increased from mild dysplasia to carcinoma in situ within the dysplasia classification, whereas in the OSCC classification, the highest overexpression was observed in the well-differentiated group.
Conclusion: Early invasive OSCC exhibited more aggressive behavior than micro-invasive OSCC, although both were less aggressive than invasive OSCC. These findings may aid in improving prognostic accuracy and informing treatment strategies.

Keywords

References

  1. Biochem J. 1999 Jul 15;341 ( Pt 2):277-84 [PMID: 10393083]
  2. Mol Cancer. 2010 Mar 02;9:48 [PMID: 20196862]
  3. Genome Biol. 2018 Jul 24;19(1):95 [PMID: 30041675]
  4. Ou Daigaku Shigakushi. 1990 Nov;17(3):372-94 [PMID: 2132328]
  5. Braz J Otorhinolaryngol. 2021 May-Jun;87(3):346-352 [PMID: 33339760]
  6. Oncol Rep. 2011 Mar;25(3):599-607 [PMID: 21234520]
  7. Am J Pathol. 1999 Feb;154(2):385-94 [PMID: 10027397]
  8. Cureus. 2023 May 2;15(5):e38467 [PMID: 37273383]
  9. J Oral Pathol. 1985 Aug;14(7):559-64 [PMID: 3928850]
  10. BMJ Glob Health. 2020 Jul;5(7): [PMID: 32665375]
  11. J Histotechnol. 2020 Sep;43(3):147-152 [PMID: 32496961]
  12. Am J Cancer Res. 2016 Jan 15;6(2):370-86 [PMID: 27186410]
  13. Indian J Dent Res. 2014 May-Jun;25(3):305-10 [PMID: 25098985]
  14. Mod Pathol. 2002 Mar;15(3):229-54 [PMID: 11904340]
  15. Biochem Biophys Res Commun. 2008 Aug 15;373(1):36-41 [PMID: 18539139]
  16. J Clin Med. 2021 Apr 13;10(8): [PMID: 33924500]
  17. Indian J Cancer. 2015 Oct-Dec;52(4):617-22 [PMID: 26960495]
  18. Scientifica (Cairo). 2015;2015:135298 [PMID: 26558136]
  19. J Clin Oncol. 2003 Dec 15;21(24):4546-52 [PMID: 14597742]
  20. Oral Oncol. 2013 Jun;49(6):598-603 [PMID: 23473850]
  21. J Clin Exp Dent. 2017 Dec 01;9(12):e1418-e1424 [PMID: 29410757]
  22. J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):159 [PMID: 31110440]
  23. Clin Otolaryngol. 2010 Oct;35(5):364-72 [PMID: 21108746]
  24. Acta Anat (Basel). 1998;161(1-4):36-78 [PMID: 9780351]
  25. Oncologist. 2004;9(3):302-11 [PMID: 15169985]
  26. J Oral Sci. 2015 Jun;57(2):115-22 [PMID: 26062860]
  27. J Inflamm Res. 2022 Jun 17;15:3561-3572 [PMID: 35747250]
  28. Head Neck Pathol. 2021 Jun;15(2):461-468 [PMID: 32918712]
  29. Oral Oncol. 2010 Jun;46(6):414-7 [PMID: 20400366]
  30. Oral Dis. 2011 Apr;17(3):298-303 [PMID: 20860767]
  31. Arch Pathol Lab Med. 2019 Apr;143(4):439-446 [PMID: 30500296]
  32. J Clin Oncol. 2008 Jan 20;26(3):354-60 [PMID: 18202409]
  33. J R Soc Interface. 2018 Jun;15(143): [PMID: 29875280]
  34. Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):528-532 [PMID: 29323067]
  35. Pol J Pathol. 2022;73(3):244-254 [PMID: 36734439]
  36. Am J Surg. 1963 Nov;106:791-6 [PMID: 14078733]
  37. CA Cancer J Clin. 2017 Jan;67(1):51-64 [PMID: 28076666]
  38. J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):19-27 [PMID: 31110412]
  39. Int J Mol Sci. 2019 Feb 06;20(3): [PMID: 30736372]
  40. Curr Health Sci J. 2015 Apr-Jun;41(2):126-134 [PMID: 30364917]
  41. Mod Pathol. 2017 Jan;30(s1):S112-S118 [PMID: 28060368]
  42. J Oral Med. 1968 Jul;23(3):91-8 [PMID: 5248004]
  43. Ann Diagn Pathol. 2020 Jun;46:151493 [PMID: 32179442]
  44. Am J Rhinol Allergy. 2020 Nov;34(6):800-809 [PMID: 32551858]
  45. Curr Opin Genet Dev. 2015 Feb;30:1-6 [PMID: 25555261]
  46. Ann Med Health Sci Res. 2015 Jul-Aug;5(4):299-304 [PMID: 26229720]
  47. J Cell Biol. 1998 Feb 9;140(3):647-57 [PMID: 9456324]
  48. J Natl Cancer Inst. 1998 Oct 21;90(20):1545-51 [PMID: 9790547]
  49. Adv Anat Pathol. 2006 Mar;13(2):83-8 [PMID: 16670463]
  50. Head Neck Pathol. 2022 Mar;16(1):54-62 [PMID: 35312982]
  51. Pathologe. 1987 May;8(3):138-40 [PMID: 3303008]
  52. Iran J Cancer Prev. 2016 Aug 15;9(4):e4467 [PMID: 27761209]
  53. Acta Neuropathol. 2006 Jun;111(6):563-8 [PMID: 16718353]

Word Cloud

Created with Highcharts 10.0.0OSCCPDPNoraldysplasiavariouscarcinomasquamouscellinvasionsamplesteststainingobservedclassificationinvasiveaggressiveObjective:studyaimedinvestigatingrolespodoplaninmarkerassociatedmalignantdevelopmentprogressionpoorprognosisleukoplakiaformsparticularlyrelationextentMethods:Immunohistochemicalanalysisconducted77histologicallyconfirmedformalin-fixedparaffin-embeddedrepresentingdegreesgradesResults:analyzedFisher'sexactKruskal-WallisSignificantassociationssampletypeintensitypercentagedistributionlocationinflammationlymphaticvesselinvolvementaccordingp < 005scoreprogressivelyincreasedmildsituwithinwhereashighestoverexpressionwell-differentiatedgroupConclusion:Earlyexhibitedbehaviormicro-invasivealthoughlessfindingsmayaidimprovingprognosticaccuracyinformingtreatmentstrategiesPodoplaninexpressiontypesD2-40DysplasiaMalignancyOralSCC

Similar Articles

Cited By

No available data.